Navigation Links
CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
Date:7/1/2008

Lab to promote collaborative ventures between Belmont's School of Pharmacy

and health care providers

NASHVILLE, Tenn., July 1 /PRNewswire/ -- Cumberland Emerging Technologies, Inc. (CET) today announced that Belmont University has established the Belmont School of Pharmacy Department of Pharmaceutical Sciences Laboratory at the CET Life Sciences Center. The Life Sciences Center, which is located in downtown Nashville, provides lab and office space, equipment and infrastructure to early-stage biopharmaceutical ventures.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080701/CLTU108 )

Belmont has leased the space to support research and service programs of its School of Pharmacy. The primary objective of the lab is to provide dosage form development, characterization and quality analysis. The school will work with the pharmaceutical industry and local and regional health care providers to meet previously unmet and emerging needs related to drug delivery.

The work being performed at the Life Sciences Center is designed to help provide drug delivery solutions, which is unique to pharmacy practice and which, until now, has not played a major role in middle Tennessee's robust health care scene," said Dr. Andrew Webster, Chair and Professor of Pharmaceutical Sciences at Belmont's School of Pharmacy. "By partnering with CET, our faculty and students have access to a community of resources to advance research that will help drug developers bring their products to patients who need them most."

"We are delighted to welcome Belmont School of Pharmacy to our growing roster of tenants at the Life Sciences Center," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals and CET. "Partnering with outstanding academic research and training programs like this one is a key component of CET's strategy, and we look forward to providing laboratory and equipment infrastructure to support their promising research."

Belmont's School of Pharmacy announced last week that it has received approval from The Accreditation Council for Pharmacy Education (ACPE) to seat its first class of 75 students for the 2008-09 academic year.

Belmont University, host of the 2008 Town Hall Presidential Debate, is a fast-growing community of nearly 4,800 students who come from almost every state and more than 25 countries. Committed to being a leader among teaching universities, Belmont brings together the best of liberal arts and professional education in a Christian community of learning and service. Belmont's purpose is to help students explore their passions and develop their talents to meet the world's needs. With more than 75 areas of study, 12 master's programs and three doctoral degrees, there is no limit to the ways Belmont University can expand an individual's horizon. For more information, visit http://www.belmont.edu.

Cumberland Emerging Technologies, Inc. (http://www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.


'/>"/>
SOURCE Cumberland Emerging Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology:
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
Breaking Biology News(10 mins):